Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2007-05-09
2009-06-09
Parkin, Jeffrey S. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C424S208100
Reexamination Certificate
active
07544467
ABSTRACT:
The present invention provides isolated cells that comprise, integrated into the genome of the cell, a transcription-competent immunodeficiency virus or a transcription-competent immunodeficiency virus-based retroviral vector. Under basal in vitro culture conditions, the immunodeficiency virus is latent, and the expression of the latent immunodeficiency virus can be reactivated. The invention farther provides methods of making a subject cell. The invention further provides screening methods for identifying agents that activate a latent immunodeficiency virus; and screening method for identifying agents that block reactivation of latent immunodeficiency virus expression in response to T cell activation signals. The invention further provides agents identified in the subject screening assays. The invention further provides methods of treating an immunodeficiency virus infection.
REFERENCES:
patent: 5256534 (1993-10-01), Butera et al.
patent: 5459056 (1995-10-01), Powell et al.
patent: 6225048 (2001-05-01), Soderberg-Naucler et al.
Chen, B., et al., 1994, Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses, J. Virol. 68(2):654-660.
Jordan, A., et al., 2003, HIV reproducibly establishes a latent infection after acute infection of T cells in vitiro, The EMBO J., 22(8):1868-1877.
Antoni et al. (1994)Virol. 202:684-694.
Bakri, Y. et al. The Maturation of Dendritic Cells Results in Postintegration Inhibition of HIV-1 Replicon. They Journal of Immunology. 2001 vol. 166, pp. 3780-3788, see abstract, and pp. 3781-2782.
Carteau et al. (1998)J. Virol. 72:4005-4014.
Chen et al. “Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses” Journal of Virology, The American Society for Microbiology, US, vol. 68, No. 2, Feb. 1994, pp. 654-660.
Emiliani et al. (1996)Proc. Natl. Acad. Sci. USA93:6377-6381.
Emiliani et al. (1998)J. Virol. 72:1666-1670.
Jordan et al. “Hiv Reproducibly Establishes a Latent Infection After Acute Infection of T Cells in Vitro”, The EMBO Journal, 2003, vol. 22, No. 8, pp. 1868-1877.
Jordan et al. “The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation” EMBO (European Molecular Biology Organization) Journal, vol. 20, No. 7, Apr. 2001, pp. 1726-1738.
Kulkosky et al. (2001)Blood, 98:3006-3015.
Latham et al. “Expression of Human Immunodeficiency Virus Long Terminal Repeat in the Human Promonocyte Cell Line U937 Effect of Endotoxin and Cytokines” Cellular Immonology, vol. 129, No. 2, 1990, pp. 513-518.
Lewinski et al., “Genome-Wide Analysis of Chrosomal Features Repressing Human Immunodeficiency Virus Transcription”, Journal of Virology, 2005, vol. 79, No. 11, pp. 6610-6619.
Sylvie Legrand-Poels et al. “Activation of Human Immunodeficiency Virus Type 1 by Oxidative Stress”, Aids Research and Human Retroviruses 1990 vol. 6, No. 12, pp. 1389-1397, abstract, Figure 4, and 1395, col. 1, last paragraph.
Valerie et al. “Activation of human immunodeficiency virus type 1 by DNA damage in human cells” Nature 1988, pp. 78-81.
Van Lint et al. “Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to the histone acetylation” EMBO (European Molecular Biology Organization) Journal, vol. 15, No. 5, 1996, pp. 1112-1120.
Verdin et al. “A new in vitro model for HIV latency” Journal of Human Virology, vol. 5, No. 1, Jan. 2002, p. 60 & 2002 International Meeting of the Institute of Human Virology; Baltimore, Maryland, USA; Sep. 9-13, 2002.
Jordan Albert
Verdin Eric M.
Borden Paula A.
Bozicevic Field & Francis LLP
Parkin Jeffrey S.
The J. David Gladstone Institutes
LandOfFree
Method for the identification of compounds capable of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the identification of compounds capable of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the identification of compounds capable of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4117423